{'_data': [['Unknown',
            [['GI',
              u'With prolonged treatment in clinical trials with a limited number of patients for up to 2 years for adults, and up to 6 months for paediatric patients 6 to 14 years of age, the safety profile did not change. The following adverse reactions have been reported in post-marketing use: Infections and infestations Upper respiratory infection Blood and lymphatic system disorders increased bleeding tendency Immune system disorders hypersensitivity reactions including anaphylaxis, hepatic eosinophilic infiltration Psychiatric disorders dream abnormalities including nightmares, hallucinations, insomnia, somnambulism, irritability, anxiety, restlessness, agitation including aggressive behaviour or hostility, tremor, depression, suicidal thinking and behaviour (suicidality) in very rare cases. Nervous system disorders dizziness, drowsiness, paraesthesia/hypoesthesia, seizure Cardiac disorders palpitations Respiratory, thoracic and mediastinal disorders Epistaxis Gastro-intestinal disorders diarrhoea, dry mouth, dyspepsia, nausea, vomiting Hepatobiliary disorders elevated levels of serum transaminases (ALT, AST), hepatitis (including cholestatic, hepatocellular, and mixed-pattern liver injury) Skin and subcutaneous tissue disorders angioedema, bruising, urticaria, pruritus, rash , erythema nodosum Musculoskeletal and connective tissue disorders arthralgia, myalgia including muscle cramps General disorders and administration site conditions asthenia/fatigue, malaise, oedema, pyrexia Very rare cases of Churg-Strauss Syndrome (CSS) have been reported during montelukast treatment in asthmatic patients (see section 4.4).']]]],
 '_pages': [5, 7],
 u'_rank': 1,
 u'_type': u'LSFU'}